NURIX THERAPEUTICS, INC. Financing Cash Flow
NURIX THERAPEUTICS, INC. (NRIX) reported Financing Cash Flow of $20.04 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-05-31 was $66.00K, a 1000.00% increase year-over-year.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-02-28 was $19.98M, a 1256.08% increase year-over-year.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-11-30 was $236.01M, a 17.70% increase year-over-year.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-08-31 was $1.16M, a 97.48% decline year-over-year.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $238.64M, a 50.86% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $485.67M, a 14996.89% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $3.22M, a 97.25% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $117.19M, a 23.84% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-05-31 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $20.04M 10-Q · filed 2026-07-09 | $256.05M derived: sum of 3 quarters · filed 2026-07-09 | $257.20M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $19.98M 10-Q · filed 2026-04-08 | $255.98M derived: sum of 2 quarters · filed 2026-04-08 | $257.14M derived: sum of 3 quarters · filed 2026-04-08 | $257.14M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $236.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $237.16M derived: sum of 2 quarters · filed 2026-01-28 | $237.17M derived: sum of 3 quarters · filed 2026-07-09 | $238.64M 10-K · filed 2026-01-28 |
| 2025-08-31 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $1.16M derived: sum of 2 quarters · filed 2026-07-09 | $2.63M 10-Q · filed 2025-10-09 | $203.16M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $1.48M 10-Q · filed 2026-07-09 | $202.00M derived: sum of 3 quarters · filed 2026-07-09 | $247.77M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $1.47M 10-Q · filed 2026-04-08 | $201.99M derived: sum of 2 quarters · filed 2026-04-08 | $247.76M derived: sum of 3 quarters · filed 2026-04-08 | $485.52M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $200.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $246.29M derived: sum of 2 quarters · filed 2026-01-28 | $484.04M derived: sum of 3 quarters · filed 2026-01-28 | $485.67M 10-K · filed 2026-01-28 |
| 2024-08-31 | $45.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $283.52M derived: sum of 2 quarters · filed 2025-10-09 | $285.15M 10-Q · filed 2025-10-09 | $285.15M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $237.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $239.38M 10-Q · filed 2025-07-09 | $239.38M derived: sum of 3 quarters · filed 2026-01-28 | $241.09M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $1.62M 10-Q · filed 2025-04-08 | $1.63M derived: sum of 2 quarters · filed 2026-01-28 | $3.33M derived: sum of 3 quarters · filed 2026-01-28 | $3.36M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $1.71M derived: sum of 2 quarters · filed 2026-01-28 | $1.74M derived: sum of 3 quarters · filed 2026-01-28 | $3.22M 10-K · filed 2026-01-28 |
| 2023-08-31 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $1.73M derived: sum of 2 quarters · filed 2024-10-11 | $3.21M 10-Q · filed 2024-10-11 | $3.08M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $1.51M 10-Q · filed 2024-07-11 | $1.37M derived: sum of 3 quarters · filed 2025-01-28 | $116.78M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $1.48M 10-Q · filed 2024-04-10 | $1.35M derived: sum of 2 quarters · filed 2025-01-28 | $116.75M derived: sum of 3 quarters · filed 2025-01-28 | $117.19M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $115.27M derived: sum of 2 quarters · filed 2025-01-28 | $115.70M derived: sum of 3 quarters · filed 2025-01-28 | $117.19M 10-K · filed 2025-01-28 |
| 2022-08-31 | $115.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $115.84M derived: sum of 2 quarters · filed 2023-10-12 | $117.33M 10-Q · filed 2023-10-12 | $117.83M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $1.92M 10-Q · filed 2023-07-13 | $2.42M derived: sum of 3 quarters · filed 2023-07-13 | $3.97M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $1.49M 10-Q · filed 2023-04-13 | $1.99M derived: sum of 2 quarters · filed 2023-04-13 | $3.54M derived: sum of 3 quarters · filed 2023-04-13 | $154.01M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.05M derived: sum of 2 quarters · filed 2023-02-09 | $152.52M derived: sum of 3 quarters · filed 2023-02-09 | $153.88M 10-K · filed 2023-02-09 |
| 2021-08-31 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $152.02M derived: sum of 2 quarters · filed 2022-10-06 | $153.38M 10-Q · filed 2022-10-06 | $152.26M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $150.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $151.83M 10-Q · filed 2022-07-07 | $150.70M derived: sum of 3 quarters · filed 2022-07-07 | $371.12M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $1.36M 10-Q · filed 2022-04-08 | $233.00K derived: sum of 2 quarters · filed 2022-04-08 | $220.65M derived: sum of 3 quarters · filed 2022-04-08 | $340.34M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $219.29M derived: sum of 2 quarters · filed 2022-01-28 | $338.98M derived: sum of 3 quarters · filed 2022-01-28 | $339.02M 10-K · filed 2022-01-28 |
| 2020-08-31 | $220.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $340.10M derived: sum of 2 quarters · filed 2021-10-14 | $340.15M 10-Q · filed 2021-10-14 | $340.23M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $119.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $119.73M 10-Q · filed 2021-07-13 | $119.81M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $46.00K 10-Q · filed 2021-04-13 | $126.00K derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $126.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $46.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |